within Pharmacolibrary.Drugs.ATC.S;

model S01BC07
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 3.3333333333333333e-06,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01BC07</td></tr><td>route:</td><td>ophthalmic</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Bendazac is a nonsteroidal anti-inflammatory drug (NSAID) that was historically used in ophthalmic formulations to treat cataracts and other inflammatory eye conditions. It is not widely approved or in common clinical use today.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic data. Below values are rough estimates for topical ophthalmic administration in adults.</p><h4>References</h4><ol><li><p>Valeri, P, et al., &amp; Silvestrini, B (1985). Investigations on the ocular pharmacokinetics of bendazac in rabbits. <i>Experimental and molecular pathology</i> 43(3) 283–287. DOI:<a href=\"https://doi.org/10.1016/0014-4800(85)90065-6\">10.1016/0014-4800(85)90065-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/4065307/\">https://pubmed.ncbi.nlm.nih.gov/4065307</a></p></li><li><p>Valeri, P, et al., &amp; Catanese, B (1987). Absorption of bendazac lysine after topical application to the rabbit eye. <i>Pharmacological research communications</i> 19(8) 517–525. DOI:<a href=\"https://doi.org/10.1016/0031-6989(87)90089-0\">10.1016/0031-6989(87)90089-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3432319/\">https://pubmed.ncbi.nlm.nih.gov/3432319</a></p></li><li><p>Abdelkader, H, &amp; Fathalla, Z (2018). Investigation into the Emerging Role of the Basic Amino Acid L-Lysine in Enhancing Solubility and Permeability of BCS Class II and BCS Class IV Drugs. <i>Pharmaceutical research</i> 35(8) 160–None. DOI:<a href=\"https://doi.org/10.1007/s11095-018-2443-0\">10.1007/s11095-018-2443-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29916057/\">https://pubmed.ncbi.nlm.nih.gov/29916057</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01BC07;
